These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

991 related items for PubMed ID: 23605247

  • 21. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J.
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [Abstract] [Full Text] [Related]

  • 22. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 23. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 24. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L.
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [Abstract] [Full Text] [Related]

  • 25. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E.
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [Abstract] [Full Text] [Related]

  • 26. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J, Huang C, Wu S, Xu Y, Cai T, Chai S, Yang Z, Sun F, Zhan S.
    PLoS One; 2017 Sep; 12(12):e0187537. PubMed ID: 29206832
    [Abstract] [Full Text] [Related]

  • 27. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM.
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [Abstract] [Full Text] [Related]

  • 28. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT.
    Ann Intern Med; 2015 Nov 03; 163(9):663-72. PubMed ID: 26457538
    [Abstract] [Full Text] [Related]

  • 29. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, Li L, Dudley JT, Johnson KW, Shervey MM, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich CG, Weaver J, Schuemie MJ, Ryan PB, Callahan A, Shah NH.
    JAMA Netw Open; 2018 Aug 03; 1(4):e181755. PubMed ID: 30646124
    [Abstract] [Full Text] [Related]

  • 30. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 31. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP.
    Postgrad Med; 2011 Jul 29; 123(4):46-53. PubMed ID: 21680988
    [Abstract] [Full Text] [Related]

  • 32. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M, Lam S.
    Cardiol Rev; 2007 Jul 29; 15(5):264-71. PubMed ID: 17700385
    [Abstract] [Full Text] [Related]

  • 33. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P.
    J Clin Pharm Ther; 2012 Aug 29; 37(4):386-98. PubMed ID: 22191695
    [Abstract] [Full Text] [Related]

  • 34. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J, Patterson S, O'Harte FP, Bell PM.
    Metabolism; 2011 Jan 29; 60(1):52-6. PubMed ID: 20152998
    [Abstract] [Full Text] [Related]

  • 35. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ.
    Clin Ther; 2011 May 29; 33(5):528-76. PubMed ID: 21665041
    [Abstract] [Full Text] [Related]

  • 36. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K.
    Drug Des Devel Ther; 2013 May 29; 7():989-1001. PubMed ID: 24068868
    [Abstract] [Full Text] [Related]

  • 37. Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
    Derosa G, Maffioli P.
    Diabetes Technol Ther; 2012 Apr 29; 14(4):350-64. PubMed ID: 22324384
    [Abstract] [Full Text] [Related]

  • 38. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.
    Deacon CF, Holst JJ.
    Expert Opin Pharmacother; 2013 Oct 29; 14(15):2047-58. PubMed ID: 23919507
    [Abstract] [Full Text] [Related]

  • 39. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
    Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF.
    Clin Exp Pharmacol Physiol; 2015 Oct 29; 42(10):999-1024. PubMed ID: 26173919
    [Abstract] [Full Text] [Related]

  • 40. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM, Mogensen UM, Andersson C, Vaag A, Torp-Pedersen C.
    Diabetes Obes Metab; 2014 Mar 29; 16(3):231-6. PubMed ID: 24020750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.